Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

Published:2020-04 Issue:4 Volume:21 Page:541-550
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Davis Kara L,Fox Elizabeth,Merchant Melinda S,Reid Joel M,Kudgus Rachel A,Liu Xiaowei,Minard Charles G,Voss Stephan,Berg Stacey L,Weigel Brenda J,Mackall Crystal L

Funder

Bristol-Myers Squibb

Children's Oncology Group

National Cancer Institute of the National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Declining childhood and adolescent cancer mortality;Smith;Cancer,2014

2. Treatment outcomes in children and adolescents with relapsed or progressed solid tumors: a 20-year, single-center study;Cho;J Korean Med Sci,2018

3. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018

4. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study;Mossé;J Clin Oncol,2017

5. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study;Laetsch;Lancet Oncol,2018

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment;Biomaterials;2025-01

2. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study);European Journal of Cancer;2024-11

3. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study;Advances in Therapy;2024-09-14

4. Advances on immunotherapy for osteosarcoma;Molecular Cancer;2024-09-09

5. Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark;Pediatric Blood & Cancer;2024-08-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3